NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Doktornolittle,

DCs, if properly activated, can manipulate their environment to get antigens to present themselves that would otherwise remain hidden. With DCVax-L they must first present the antigens they picked up from the lysate to T-cells in the lymph zone so that these T-cells have all the neoantigens and hidden antigens that DCVax was able to pick up. This is why saving all the resected tumor for lysing is so important since individual antigen types are not necessarily evenly distributed throughout the tumor. Once these T-cells are properly targeted then they return to the site of active immune response signalling which is done by the DCs. If the DCs move off site too quickly the tumor environment changes which allows the cancer signaling to hide critical targets from the T-cells again and signals all is well. This is why flipper44 and I believe the dosing and treatment schedule is critical to the success of DCVax and the Phase 3 trial is better on both of these counts than in previous trials.